No Data
No Data
No Data
No Data
No Data
Betta Pharmaceutical (300558.SZ): Thebesilil tartrate capsules completed phase III clinical trials and obtained a summary report
Zhitong Finance App News, Betta Pharmaceutical (300558.SZ) issued an announcement. After completing the phase III clinical trial of the company's self-developed project BPI-16350 (tebesilil tartrate capsules), a clinical trial summary report has been obtained through a series of statistical data analysis work. This drug, in combination with fluvirizin, is suitable for patients with locally advanced or advanced recurrent metastatic breast cancer with positive hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2), which progresses after previous endocrine treatment. The study results showed that, based on the researcher's evaluation, the BPI-16350+ fluvir group was previously accepted
Zhitong FinanceApr 24 05:38 ET
Betta Pharmaceuticals (300558.SZ): Currently, there are no stem cell drugs on the market or research projects for diabetes treatment
Gelonghui, April 22 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company currently has no stem cell drugs on the market or set up research projects to treat diabetes.
Gelonghui FinanceApr 22 03:31 ET
Betta Pharmaceuticals (300558.SZ) reported first-quarter results, net profit of 98.1407 million yuan, an increase of 90.95% year-on-year
Betta Pharmaceuticals (300558.SZ) released its report for the first quarter of 2024, with revenue of 736 million yuan, compared with...
Zhitong FinanceApr 19 07:00 ET
Some Shareholders Feeling Restless Over Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Ratio
With a price-to-earnings (or "P/E") ratio of 45.3x Betta Pharmaceuticals Co., Ltd. (SZSE:300558) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E
Simply Wall StApr 15 23:41 ET
Betta Pharmaceuticals (300558.SZ): Currently, there are no stem cell-related drugs on the market or the establishment of research projects
On April 15, Gelonghui | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company currently has no stem cell-related drugs on the market or set up research projects. In May 2023, the company invested in the introduction of the CFT8919 project, a modified BiDAC (bifunctional protein degrading agent) with oral bioavailability, which has good activity and selectivity for carrying EGFR L858R mutations. Currently, the development of this new drug is progressing according to plan.
Gelonghui FinanceApr 15 04:03 ET
Betta Pharmaceuticals (300558.SZ): Befotinib has not conducted clinical studies on indications related to 20 exon insertion
Glonghui, April 9丨An investor asked Betta Pharmaceuticals (300558.SZ) on the investor interactive platform, “Has your company carried out domestic clinical research on 20 exon insertion indications?” The company replied that currently, befotinib has not conducted clinical studies on indications related to 20 exon insertion.
Gelonghui FinanceApr 9 04:42 ET
No Data
No Data